Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
10 studies found for:    regorafenib AND GIST | Open Studies
Show Display Options
Download search resultsDownload the search results for:
regorafenib AND GIST | Open Studies (10 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: regorafenib
2 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
3 Recruiting Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Condition: Gastrointestinal Stromal Tumour (GIST)
Intervention: Drug: regorafenib
4 Recruiting A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)
Condition: Gastrointestinal Stromal Tumour
Interventions: Drug: Regorafenib;   Drug: imatinib
5 Recruiting Regorafenib Post-marketing Surveillance in Japan
Condition: Gastrointestinal Stromal Tumors
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
6 Recruiting The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib
Conditions: Colorectal Neoplasms;   Gastrointestinal Stromal Tumors
Interventions: Drug: Esomeprazole 40mg concomitantly;   Drug: Esomeprazole 40mg before;   Drug: Regorafenib 160mg or 120mg
7 Not yet recruiting Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib
Condition: Gastrointestinal Stromal Tumors (GISTs)
Intervention: Drug: Regorafenib
8 Recruiting PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: PLX9486;   Drug: PLX3397
9 Recruiting SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
10 Recruiting Stivarga Regulatory Post-Marketing Surveillance Study in Korea
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga,BAY73-4506)

Indicates status has not been verified in more than two years